Juan Luis Mendoza

Juan Luis Mendoza

Auto-generated profile, based on publicly available information

Juan Luis Mendoza

Howard Hughes Medical Institute at University of Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Cell
Verified
Journal Article
Closed access
MBMichael E. Birnbaum
Michael E. Birnbaum
JMJuan L. Mendoza
Juan L. Mendoza
DSDhruv K. Sethi
Dhruv K. Sethi
SDShen Dong
Shen Dong
JGJacob Glanville
Jacob Glanville
KGK. Christopher Garcia
K. Christopher Garcia

21 March 2015 in Annual Review of Immunology
Verified
Journal Article
Closed access
JSJamie B. Spangler
Jamie B. Spangler
IMIgnacio Moraga
Ignacio Moraga
JMJuan L. Mendoza
Juan L. Mendoza
KGK. Christopher Garcia
K. Christopher Garcia
Cytokines exert a vast array of immunoregulatory actions critical to human biology and disease. However, the desired immunotherapeutic effects of native cytokines are often mitigated by toxicity or lack of efficacy, either of which results from cytokine receptor pleiotropy and/or undesired activation of off-target cells. As our understanding of the structural principles of cytokine–receptor interactions has advanced, mechanism-based manipulation of cytokine signaling through protein engineering has become an increasingly feasible and powerful approach. Modified cytokines, both agonists and antagonists, have been engineered with narrowed target cell specificities, and they have also yielded important mechanistic insights into cytokine biology and signaling. Here we review the theory and practice of cytokine engineering and rationalize the mechanisms of several engineered cytokines in the context of structure. We discuss specific examples of how structure-based cytokine engineering has opened new opportunities for cytokines as drugs, with a focus on the immunotherapeutic cytokines interferon, interleukin-2, and interleukin-4.

1 January 2018 in Cell
Verified
Journal Article
Closed access
MGMarvin H. Gee
Marvin H. Gee
AHArnold Han
Arnold Han
SLShane M. Lofgren
Shane M. Lofgren
JBJohn F. Beausang
John F. Beausang
JMJuan L. Mendoza
Juan L. Mendoza
KGK. Christopher Garcia
K. Christopher Garcia

1 January 2012 in Cell
Verified
Journal Article
Closed access
JMJuan L. Mendoza
Juan L. Mendoza
ASAndré Schmidt
André Schmidt
QLQin Li
Qin Li
ENEmmanuel Nuvaga
Emmanuel Nuvaga
TBTyler Barrett
Tyler Barrett
PTPhilip J. Thomas
Philip J. Thomas

19 October 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
OOOlusegun O. Onabajo
Olusegun O. Onabajo
ABA. Rouf Banday
A. Rouf Banday
MSMegan Stanifer
Megan Stanifer
WYWusheng Yan
Wusheng Yan
AOAdeola Obajemu
Adeola Obajemu
LPLudmila Prokunina-Olsson
Ludmila Prokunina-Olsson

1 November 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PTPatrick H. Thibodeau
Patrick H. Thibodeau
JRJohn M. Richardson
John M. Richardson
WWWei Wang
Wei Wang
LMLinda Millen
Linda Millen
JWJarod Watson
Jarod Watson
PTPhilip J. Thomas
Philip J. Thomas
The deletion of phenylalanine 508 in the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator is directly associated with >90% of cystic fibrosis cases. This mutant protein fails to traffic out of the endoplasmic reticulum and is subsequently degraded by the proteasome. The effects of this mutation may be partially reversed by the application of exogenous osmolytes, expression at low temperature, and the introduction of second site suppressor mutations. However, the specific steps of folding and assembly of full-length cystic fibrosis transmembrane conductance regulator (CFTR) directly altered by the disease-causing mutation are unclear. To elucidate the effects of the ΔF508 mutation, on various steps in CFTR folding, a series of misfolding and suppressor mutations in the nucleotide binding and transmembrane domains were evaluated for effects on the folding and maturation of the protein. The results indicate that the isolated NBD1 responds to both the ΔF508 mutation and intradomain suppressors of this mutation. In addition, identification of a novel second site suppressor of the defect within the second transmembrane domain suggests that ΔF508 also effects interdomain interactions critical for later steps in the biosynthesis of CFTR.